The Medical and Health Bureau announced on Monday night (7th) that Fosun Pharma, the agent for Fubitai’s vaccine, had earlier applied for its bivalent vaccine (Omicron variant BA.4-5 bivalent new crown vaccine) to Director Lu Chongmao for emergency use. And submit the overseas approval of the vaccine, as well as information related to the safety, efficacy and quality of the vaccine.
The Advisory Committee of Experts held a meeting today and generally approved the submitted information and reports, but required the applicant to continue to submit the latest clinical data and quality certificates and other documents, and to submit suggestions to Lu Chongmao.
Expert committee: Boosters outweigh risks for prevention
The Vaccine Advisory Expert Committee was chaired by the convener, Liu Zexing, and held a meeting on Monday to discuss the application for emergency use of the Fosun Pharma bivalent vaccine (Omicron variant BA.4-5 bivalent new crown vaccine).
The committee endorsed the use of the bivalent vaccine, arguing that as a booster, the benefits of preventing the virus outweigh the risks.
In order to ensure the continued safety, efficacy and quality assurance of the relevant vaccines, the committee recommends adding conditions to require applicants to continue to submit the latest clinical data, safety update reports, and quality certification documents for each batch of vaccines produced by the pharmaceutical factory.
The Advisory Committee of Experts will sort out the opinions and submit suggestions to Lu Chongmao for consideration.
▼September 1st, the first day of vaccination services provided by private clinics in Causeway Bay▼
+14
Proposed bivalent vaccine for people over 12 years of age as the fourth dose
The Scientific Committee on Vaccine-Preventable Diseases, the Scientific Committee on Emerging Discoveries and Animal Infectious Diseases, together with the Chief Executive's Expert Advisory Panel, have earlier suggested that the bivalent vaccine should be used by eligible persons aged 12 or above, and that the current vaccination schedule should be used instead of The original virus strain vaccine is the fourth dose.
The authorities added that the original virus strain vaccine could also be used as a fourth dose.
A government spokesman said that the Advisory Committee of Experts welcomes the approval of the vaccine and submits its recommendations. He pointed out that the Secretary will consider the relevant recommendations and approve the emergency use of the approved vaccine as soon as possible. vaccination.
Kong Fanyi pointed out that the bivalent vaccine is more effective than the first generation and will be updated continuously. Vaccination may be required before winter every year | The Science and Technology Committee adopted the introduction of the bivalent vaccine as the fourth booster dose to arrive in Hong Kong as soon as January next year | Should the bivalent vaccine be introduced? Talking about Liu Yulong's claim of wasting resources: worrying about citizens' illusions and other new vaccines
